U.S. Stock Market Midday Update
Theriva Biologics fell 23.22%. Based on recent key news:
<ol>
<li>
On April 17, Theriva Biologics announced that it would present additional data from the VIRAGE 2B clinical trial at the AACR 2026 Annual Meeting, involving the application of VCN-01 in metastatic pancreatic cancer. This news drove the stock price up as investors increased their expectations for the new data.
</li>
<li>
On April 20, the company stated that it had reached an agreement with the FDA and EMA to conduct a pivotal Phase 3 clinical trial of VCN-01 in first-line metastatic pancreatic cancer patients. This move enhanced market confidence in the potential of its drug, further driving the stock price up.
</li>
<li>
On April 18, Theriva Biologics released poster data showing that the combination of VCN-01 with chemotherapy drugs could improve overall survival and progression-free survival. This result boosted investor confidence in its therapeutic effects, leading to a rise in stock price. The biotechnology industry has been active recently, with significant capital inflows.
</li>
</ol>
Top Stocks by Trading Volume in the Industry
AbbVie fell 0.27%. Based on recent key news:
<ol>
<li>
On April 20, AbbVie expanded its collaboration with BioLabs to the University of Toronto to accelerate life sciences research. This initiative aims to support early-stage startups by providing laboratory and collaborative space, influencing stock price volatility.
</li>
<li>
On April 20, AbbVie paid $10 million in milestone payments to Japan's Nxera Pharma, marking progress in their collaboration on neurological diseases. This payment reflects the ongoing advancement of the partnership, impacting the stock price.
</li>
<li>
On April 20, AbbVie conducted digital advertising campaigns in Times Square, New York, to expand its market influence. This initiative enhanced brand awareness through media and influencer collaborations, affecting the stock price. Innovation in the life sciences sector is accelerating, and the market is active.
</li>
</ol>
Aliram Pharmaceuticals fell 2.53%. Based on recent key news:
<ol>
<li>
On April 20, Aliram Pharmaceuticals' stock price approached an all-time high, with significantly increased trading volume. Technical indicators show positive signals, potentially providing breakthrough momentum in the short term, but high-level pressure cannot be ignored. Investor sentiment is leaning towards optimism, but caution is needed regarding the short-term adjustment risks from unsustainable volume. Source: Zhito Finance
</li>
<li>
On April 20, China Galaxy Securities released a research report stating that the small nucleic acid industry chain is in its early stages domestically, with significant room for domestic substitution, and CXO is helping accelerate industry development. The research and development of small nucleic acid drugs is entering a boom period, with vast potential in the chronic disease market. Source: Zhito Finance
</li>
<li>
On April 19, MarketBeat did not include Aliram Pharmaceuticals in its list of top five stocks recommended by analysts, despite its rating being moderately buy. Source: MarketBeat The small nucleic acid drug industry is developing rapidly, with risk warnings: increasing macroeconomic pressures leading to insufficient pharmaceutical consumption, innovative drug insurance payments falling short of expectations, global order shifts due to geopolitical factors, and centralized procurement or pricing reductions exceeding market expectations
Amgen fell 2.22%, with increased trading volume. Based on recent key news:
</li>
<li>
On April 20, Amgen plans to expand its business in Hong Kong. This move may enhance its influence in the Asian market and drive stock price volatility. Source: South China Morning Post
</li>
<li>
On April 21, Bernstein analysts maintained a hold rating on Amgen, with a target price of $335. Analyst ratings may affect investor confidence, leading to stock price fluctuations. Source: TipRanks
</li>
<li>
On April 15, Bank of America Securities reiterated its sell rating on Amgen. The downgrade may exacerbate negative market expectations for Amgen, impacting its stock price. Source: TipRanks The Hong Kong expansion plan affects market sentiment.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Gilead Sciences fell 2.10%. Based on recent news,
<ol>
<li>
On April 21, Gilead Sciences announced the termination of its EDGE-Lung study, which evaluated the effects of domvanalimab in combination with various immunotherapies in lung cancer patients. This move raised market concerns about its R&amp;D pipeline, leading to a stock price decline.
</li>
<li>
On April 20, Gilead Sciences decided not to pay for option renewals, relinquishing certain rights to its early-stage R&amp;D projects. This decision further intensified investor doubts about its future R&amp;D investments, affecting the stock price.
</li>
<li>
On April 21, Johnson &amp; Johnson's CAR-T therapy for multiple myeloma, Carvykti, achieved sales of $1.89 billion last year, while Gilead Sciences recently paid $7.8 billion to acquire Arcellx and its competing drug. The market expressed concerns over Gilead's hefty acquisition, putting pressure on its stock price. The competition in the biopharmaceutical industry is intensifying, and the risks associated with R&amp;D investments are increasing
</li>
</ol>

TOVX

Theriva Biologics fell 23.22%; AbbVie fell 0.27%, with a transaction volume of USD 322 million; Alnylam Pharmaceuticals fell 2.53%, with a transaction volume of USD 100 million; Amgen fell 2.22%, with a transaction volume of USD 81.09 million; Gilead Sciences fell 2.10%, with a market capitalization of USD 165.1 billion

U.S. stock market midday update: Theriva Biologics stock price plummets 23.22%, market reacts lukewarm to clinical trial data?